An FDA initiative to implement real-world clinical trials could dramatically accelerate the pace at which new treatments become available to patients, according to physicians from two institutions involved in the effort’s initial phase.
The approach will leverage electronic health records and an AI-powered platform to allow FDA scientists to track safety signals and efficacy endpoints while studies are in progress. The goal is to streamline data collection and facilitate earlier regulatory decisions.
“Our capabilities for drug and device development, and our ability to evaluate data, are much
— Curated from external eye-care sources for opthametry.com readers.
📰 Original Source: Healio Optometry
Discover more from An Eye Care Blog
Subscribe to get the latest posts sent to your email.
